Effects of DLX-001 on PD, Safety, Tolerability, and PK in Participants with MDD

2024-517139-29-00 Protocol DLX-001-102 Human pharmacology (Phase I) - Other Ended

Start 6 Nov 2024 · End 6 Jun 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol DLX-001-102

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 20
Countries 1
Sites 1

Major Depressive Disorder (MDD)

Key facts

Sponsor
Delix Therapeutics Inc., Delix Therapeutics Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Mental Disorders [F03]
Trial duration
6 Nov 2024 → 6 Jun 2025
Decision date (initial)
2024-11-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Major Depressive Disorder (MDD)

VersionLevelCodeTermSystem organ class
21.1 LLT 10081270 Major depressive disorder 10037175

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Delix Therapeutics Inc.

Sponsor organisation
Delix Therapeutics Inc.
Address
20 Authors Road
City
Concord
Postcode
01742-2607
Country
United States

Scientific contact point

Organisation
Delix Therapeutics Inc.
Contact name
Aaron Koenig

Public contact point

Organisation
Delix Therapeutics Inc.
Contact name
Nicholas Pelletier

Delix Therapeutics Inc.

Sponsor organisation
Delix Therapeutics Inc.
Address
36 Crosby Drive Suite 200
City
Bedford
Postcode
01730-1442
Country
United States

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 20 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharma Bio-Research Group
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-11-06 2025-06-05 2024-11-06 2025-05-12

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-10 Netherlands Acceptable
2024-11-04
2024-11-04
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-31 Netherlands Acceptable
2025-02-05
2025-02-05
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-27 Netherlands Acceptable
2025-03-05
2025-03-05
4 SUBSTANTIAL MODIFICATION SM-3 2025-05-20 Netherlands Acceptable
2025-05-27
2025-05-27